1.40

2.10% -0.03

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $1.40, with a volume of 4.15M. It is down -2.10% in the last 24 hours and up +60.38% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Previous Close:

$1.43

Open:

$1.43

24h Volume:

4.15M

Relative Volume:

0.86

Market Cap:

$375.56M

Revenue:

$232.40M

Net Income/Loss:

$-20.51M

P/E Ratio:

-18.16

EPS:

-0.0771

Net Cash Flow:

$60.04M

1W Performance:

+12.90%

1M Performance:

+60.38%

6M Performance:

-7.89%

1Y Performance:

-64.82%

1-Day Range:

$1.36

$1.4394

1-Week Range:

$1.234

$1.46

52-Week Range:

$0.8227

$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1096)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

194

Twitter

@akebiatx

Next Earnings Date

2026-08-06

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	1.40	375.56M	232.40M	-20.51M	60.04M	-0.0771
TAK Takeda Pharmaceutical Co Adr	16.56	52.88B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.76	42.98B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.95	38.37B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.56	31.68B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.06	23.22B	3.17B	1.29B	1.01B	27.09

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Resumed	H.C. Wainwright	Buy
Apr-28-25	Initiated	Leerink Partners	Outperform
Apr-01-25	Initiated	Jefferies	Buy
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

07:44 AM

ETFs Investing in Akebia Therapeutics, Inc. Stocks - TradingView

07:44 AM

Jul 10, 2026

Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary - Quartr

Jul 10, 2026

Akebia Therapeutics (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr

Jul 10, 2026

Jul 09, 2026

Zacks Research Upgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat

Jul 09, 2026

Jul 08, 2026

Akebia Therapeutics (AKBA) Jefferies London Healthcare Conference 2025 Summary - Quartr

Jul 08, 2026

Jul 06, 2026

AKBAAkebia Therapeutics Inc Options - Finviz

Jul 06, 2026

Jul 05, 2026

Chief Business Officer Erik Ostrowski Sold A Bunch Of Shares In Akebia Therapeutics - Moomoo

Jul 05, 2026

Jul 02, 2026

Akebia awards 125,600 stock options to newly hired employees - Stock Titan

Jul 02, 2026

Jul 01, 2026

AKBA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $6.00 - GuruFocus

Jul 01, 2026

Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover - Stock Titan

Jul 01, 2026

H.C. Wainwright reiterates Akebia stock rating on trial results By Investing.com - Investing.com Canada

Jul 01, 2026

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Jul 01, 2026

Jun 30, 2026

Akebia TherapeuticsVoice Trial Meets Stopp - Moomoo

Jun 30, 2026

U.S. Renal Care and Akebia Therapeutics, Inc. Announce Interim Analysis of VOICE Trial Demonstrates Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo Versus ESA - marketscreener.com

Jun 30, 2026